Labcorp launches new test to accelerate path to diagnosis of alzheimer's disease

Test is available through physicians for use with patients being evaluated for possible alzheimer's disease or other causes of cognitive impairment labcorp is the first company to deliver a blood-based amyloid-tau-neurodegeneration (atn) profile, which uses a trio of blood biomarkers to detect the hallmarks of alzheimer's disease burlington, n.c., oct. 11, 2023 /prnewswire/ -- labcorp (nyse: lh), a global leader of innovative and comprehensive laboratory services, announced today the launch and national availability of its atn profile, a blood-based test that combines three, well-researched blood biomarkers to identify and assess biological changes associated with alzheimer's disease – amyloid plaques, tau tangles and neurodegeneration (atn) – which can help accelerate the path to diagnosis and intervention.i the test is available through physicians for use with patients who are being evaluated for possible alzheimer's disease or other causes of cognitive impairment based on clinical observation and cognitive screenings.
LH Ratings Summary
LH Quant Ranking